{"data":{"ticker":"NTRA","slug":"natera","name":"Natera","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Austin, Texas","ceo":"Steven Leonard Chapman","employees":6135,"website":"https://www.natera.com","founded":"2004","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"}],"exposure":{"score":15,"tier":"Peripheral","rationale":"Sells genetic tests like Signatera and Panorama, using ML algorithms to analyze cell-free DNA for cancer and prenatal screening. AI is core to assay accuracy, but growth is driven by diagnostic test volumes, not the AI buildout."},"quote":{"price":310.67,"change24hPct":-14.59,"change7dPct":-25.01,"change30dPct":-20.5,"change1yPct":55.67,"high52w":436,"low52w":182.65,"marketCap":44781273088,"peRatio":null,"eps":-1.12,"volume24h":1794245382},"nextEarningsDate":"2026-11-05","summary":"Natera is a genetic testing company. It sells diagnostics built on cell-free DNA, fragments of DNA circulating in blood, serving oncology, prenatal care, and organ transplant medicine, and earns revenue on test volumes.","explainer":["Natera is a genetic testing company. It sells diagnostics built on cell-free DNA, fragments of DNA circulating in blood, serving oncology, prenatal care, and organ transplant medicine, and earns revenue on test volumes.","Machine learning is what makes its tests work. Signatera detects tiny traces of circulating tumor DNA to monitor cancer, Panorama uses AI-driven analysis for prenatal screening, and Prospera applies the same approach to detecting organ transplant rejection early.","Founded in 2004 and headquartered in Austin, Texas, Natera trades on the NASDAQ and employs about 6,100 people under CEO Steve Chapman."],"buildoutRole":"Natera sits in the AI Healthcare layer, where machine learning is the scientific engine rather than a bolt-on feature. Its algorithms extract faint genetic signals from blood samples, which is what makes tests like Signatera and Panorama possible at all. Even so, the business grows on diagnostic test volumes, clinical adoption, and reimbursement, not on AI buildout spending. Supercycle gives it an AI Exposure Score of 15 out of 100.","faq":[{"q":"What does Natera do?","a":"Natera sells genetic tests based on cell-free DNA analysis, serving cancer monitoring, prenatal screening, and organ transplant medicine, and earns revenue on diagnostic test volumes."},{"q":"How is Natera exposed to AI?","a":"AI is core to its science, not its market. Machine learning makes its tests accurate, but growth depends on test volumes and clinical adoption. Supercycle scores it 15 out of 100."},{"q":"What are Natera's main products?","a":"Signatera for circulating tumor DNA cancer monitoring, Panorama for AI-driven prenatal screening, and Prospera for detecting organ transplant rejection."},{"q":"Where is Natera headquartered and who leads it?","a":"Natera is headquartered in Austin, Texas, was founded in 2004, and is led by CEO Steve Chapman. It employs about 6,100 people and trades on the NASDAQ."},{"q":"Is NTRA a pure play AI stock?","a":"No. Natera is a diagnostics company where machine learning powers the assays. Its AI Exposure Score of 15 out of 100 reflects AI as enabling science rather than the growth driver."}],"history1y":[{"date":"2026-09-28","close":411.77},{"date":"2026-09-29","close":414.52},{"date":"2026-09-30","close":413.31},{"date":"2026-10-01","close":408.47},{"date":"2026-10-02","close":410.35},{"date":"2026-10-05","close":425.64},{"date":"2026-10-06","close":400.65},{"date":"2026-10-07","close":395.56},{"date":"2026-10-08","close":390.79},{"date":"2026-10-09","close":400.71},{"date":"2026-10-12","close":397.77},{"date":"2026-10-13","close":395.65},{"date":"2026-10-14","close":394.75},{"date":"2026-10-15","close":404.79},{"date":"2026-10-16","close":393.44},{"date":"2026-10-19","close":399.42},{"date":"2026-10-20","close":405.92},{"date":"2026-10-21","close":413.38},{"date":"2026-10-22","close":401.37},{"date":"2026-10-23","close":403.95},{"date":"2026-10-26","close":404.9},{"date":"2026-10-27","close":410.82},{"date":"2026-10-28","close":424.42},{"date":"2026-10-29","close":436},{"date":"2026-10-30","close":414.3},{"date":"2026-11-02","close":378.92},{"date":"2026-11-03","close":388.63},{"date":"2026-11-04","close":391.03},{"date":"2026-11-05","close":363.76},{"date":"2026-11-06","close":310.67}],"incomeStatements":[{"ticker":"NTRA","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":2306113000,"cost_of_revenue":812933000,"gross_profit":1493180000,"operating_expense":0,"operating_income":-309911000,"net_income":-208160000,"earnings_per_share":-1.52,"earnings_per_share_diluted":-1.52,"research_and_development":624110000,"selling_general_and_administrative_expenses":1177261000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"NTRA","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":1696911000,"cost_of_revenue":673753000,"gross_profit":1023158000,"operating_expense":0,"operating_income":-222294000,"net_income":-190426000,"earnings_per_share":-1.53,"earnings_per_share_diluted":-1.53,"research_and_development":404138000,"selling_general_and_administrative_expenses":841314000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"NTRA","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":1082571000,"cost_of_revenue":589831000,"gross_profit":492740000,"operating_expense":0,"operating_income":-446245000,"net_income":-434801000,"earnings_per_share":-3.78,"earnings_per_share_diluted":-3.78,"research_and_development":320678000,"selling_general_and_administrative_expenses":618307000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"NTRA","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":820222000,"cost_of_revenue":456256000,"gross_profit":363966000,"operating_expense":0,"operating_income":-541040000,"net_income":-547799000,"earnings_per_share":-5.57,"earnings_per_share_diluted":-5.57,"research_and_development":316415000,"selling_general_and_administrative_expenses":588591000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"NTRA","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":2398344000,"current_assets":1496939000,"cash_and_equivalents":1076140000,"total_liabilities":685931000,"current_liabilities":441228000,"total_debt":214377000,"shareholders_equity":1712413000,"retained_earnings":-2776022000},{"ticker":"NTRA","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":1660735000,"current_assets":1375820000,"cash_and_equivalents":945587000,"total_liabilities":465315000,"current_liabilities":344045000,"total_debt":187118000,"shareholders_equity":1195420000,"retained_earnings":-2567862000},{"ticker":"NTRA","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":1441699000,"current_assets":1258549000,"cash_and_equivalents":642095000,"total_liabilities":676372000,"current_liabilities":307274000,"total_debt":441993000,"shareholders_equity":765327000,"retained_earnings":-2377436000},{"ticker":"NTRA","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":1394474000,"current_assets":1211817000,"cash_and_equivalents":466091000,"total_liabilities":688730000,"current_liabilities":310499000,"total_debt":446219000,"shareholders_equity":705744000,"retained_earnings":-1942635000}],"holders13f":[{"slug":"stanley-druckenmiller","personName":"Stanley Druckenmiller","fundName":"Duquesne Family Office","value":864923000,"portfolioPct":0.1986401697663416,"change":"increased","period":"2026-06-30"},{"slug":"philippe-laffont","personName":"Philippe Laffont","fundName":"Coatue Management","value":680006681,"portfolioPct":0.013983547471665045,"change":"trimmed","period":"2026-06-30"},{"slug":"cathie-wood","personName":"Cathie Wood","fundName":"ARK Investment Management","value":186989592,"portfolioPct":0.012140550297756927,"change":"increased","period":"2026-06-30"},{"slug":"andreas-halvorsen","personName":"Andreas Halvorsen","fundName":"Viking Global","value":106053886,"portfolioPct":0.0030232673364749057,"change":"new","period":"2026-06-30"},{"slug":"gavin-baker","personName":"Gavin Baker","fundName":"Atreides Management","value":28335308,"portfolioPct":0.002541673218935115,"change":"new","period":"2026-06-30"},{"slug":"ray-dalio","personName":"Ray Dalio","fundName":"Bridgewater Associates","value":1665617,"portfolioPct":0.00006832995927997307,"change":"trimmed","period":"2026-06-30"}],"news":[{"title":"It Was Already A Gory Day For Blood-Testing Stocks — Then, Natera And Guardant Reported","source":null,"url":"https://finance.yahoo.com/m/08399e0f-5b0a-3f7c-be4c-fb25e7b6b8dc/it-was-already-a-gory-day-for.html?.tsrc=rss","date":"2026-11-06"},{"title":"Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says","source":null,"url":"https://finance.yahoo.com/healthcare/articles/natera-q3-results-2029-revenue-194709976.html?.tsrc=rss","date":"2026-11-06"},{"title":"Update: Natera Shares Fall After Wider-Than-Expected Q3 Loss","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/natera-shares-fall-wider-expected-194518296.html?.tsrc=rss","date":"2026-11-06"},{"title":"Natera promotes Solomon Moshkevich to CEO","source":null,"url":"https://www.medtechdive.com/news/natera-promotes-solomon-moshkevich-to-ceo/874022/?.tsrc=rss","date":"2026-11-06"},{"title":"Natera Stocks Slide 15.07% After Wider Loss and Sudden CEO Change","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/natera-stocks-slide-15-07-171239578.html?.tsrc=rss","date":"2026-11-06"},{"title":"Natera (NTRA) Q3 2026 Earnings Call Transcript","source":null,"url":"https://www.fool.com/earnings/call-transcripts/2026/11/06/natera-ntra-q3-2026-earnings-call-transcript/?.tsrc=rss","date":"2026-11-06"},{"title":"Natera Sinks 14% as CEO Steve Chapman Steps Down Despite Q3 Beat: “An Excellent Time to Transition”","source":null,"url":"https://www.tikr.com/blog/natera-sinks-14-as-ceo-steve-chapman-steps-down-despite-q3-beat-an-excellent-time-to-transition?ref=yahoofinance&tlnk=yf-261106-3492r7hv&.tsrc=rss","date":"2026-11-06"},{"title":"What Natera (NTRA) Said on Its Q3 Earnings Call","source":null,"url":"https://www.marketbeat.com/instant-alerts/transcript-what-natera-ntra-said-on-its-q3-earnings-call-2026-11-06/?utm_source=yahoofinance&utm_medium=yahoofinance&.tsrc=rss","date":"2026-11-06"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.488Z","tier":"free","source":"https://supercyclehq.com/stock/natera","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/NTRA","html":"https://supercyclehq.com/stock/natera","md":"https://supercyclehq.com/stock/natera.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}